Excess Returns
The War No One Can Price | The Weekly Wrap – 3/22/2026
Most Important Insight
Financial markets are currently operating under a state of 'willful ignorance' regarding geopolitical risk, where war probabilities remain unpriced until the moment of conflict, creating a dangerous disconnect between low spot volatility and record-high volatility premiums.
Most Original Insight
Biotech investing should be structurally reclassified as a 'portfolio of options' rather than traditional equity, requiring a valuation model based entirely on probabilistic drug development outcomes rather than discounted cash flows.
Key Points
- Markets consistently fail to price geopolitical escalations in advance, as evidenced by the delayed reaction to the Ukraine conflict and current tensions.
- The spread between implied volatility and the VIX is at historic highs, indicating that while the market appears calm, the cost of hedging against tail risks is extremely elevated.
- Current options dealer gamma positioning is so fragile that a minor 2% to 3% decline in broad equities could trigger a mechanical VIX spike to the 40 level.
- The Federal Reserve is trapped in a 'path of least embarrassment' policy framework, struggling to balance oil-driven inflation against the resulting demand destruction.
- A fundamental macro regime shift has occurred where stock-bond correlations have flipped, permanently breaking the diversification benefits of the traditional 60/40 portfolio.
- The 'Awesome Portfolio' strategy is presented as the necessary evolution for non-stationary markets, emphasizing diversification across distinct economic regimes rather than asset classes.
- Options expiration (OPEX) cycles have become the primary tactical turning points for market direction and volatility regime shifts in 2026.
- Oil shocks are currently acting as a dual-threat to the economy, simultaneously fueling headline inflation while acting as a regressive tax that destroys consumer demand.
Investment Implications
| Asset / Sector / Instrument | Action | Source | Notes |
|---|---|---|---|
| Long-dated Equity Hedges | BUY | explicit | The shift from short-term to longer-term hedging is necessary to protect against unpriced geopolitical 'black swan' events. |
| VIX / Long Volatility | BUY | implicit | Dealer positioning suggests a massive volatility expansion is likely upon even a minor market pullback. |
| Biotech Sector | BUY | implicit | Recommended as a 'bag of options' where returns are driven by probabilistic drug pipeline successes rather than macro factors. |
| Crude Oil | HOLD | implicit | Prices are caught between inflationary supply shocks and the demand destruction the Fed is forced to navigate. |
| 60/40 Portfolio | SELL | implicit | The flip in stock-bond correlations has rendered this traditional diversification strategy ineffective in the current regime. |
Hang on a sec…
- The assertion that a 2-3% market drop would automatically spike the VIX to 40 is highly speculative; while gamma can accelerate moves, such a magnitude of VIX expansion typically requires a systemic liquidity crisis or a major exogenous shock.
- The 'path of least embarrassment' theory for Fed policy oversimplifies central bank decision-making into a psychological game, ignoring the rigorous data-dependent frameworks and legal mandates that govern interest rate paths.
- Classifying the entire biotech sector as merely a 'bag of options' ignores the fundamental value of established commercial revenue, manufacturing infrastructure, and platform technologies that provide a valuation floor independent of binary clinical trial results.